Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

摘要: Background We evaluated the efficacy of raltegravir and development viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) triple-class drug whom antiretroviral therapy had failed. Methods conducted subgroup analyses data from week 48 both studies according to baseline prognostic factors. Genotyping integrase gene was performed recipients virologic failure. Results Virologic responses consistently superior placebo, regardless values HIV-1 RNA level; CD4 cell count; genotypic or phenotypic sensitivity score; use nonuse darunavir, enfuvirtide, optimized background therapy; demographic characteristics. Among combined using enfuvirtide darunavir for first time, levels less than 50 copies per milliliter achieved 89% 68% placebo recipients. 69% 80% 47% 57% either respectively. At weeks, 105 462 (23%) 94 Integrase mutations known be associated arose during treatment 64 (68%). Forty-eight these (75%) more resistance-associated mutations. Conclusions When an regimen studies, a favorable effect over shown clinically relevant subgroups patients, including those characteristics that typically predict poor response therapy: high level, low count, score. (ClinicalTrials.gov numbers, NCT00293267 NCT00293254.)